CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma
Authors
G W Aherne
T S Benepal
+7 more
D Cunningham
H E R Ford
A Massey
T Price
S Rao
P J Ross
L Vernillet
Publication date
Publisher
Nature Publishing Group
Doi
Cite
View
on
PubMed
Abstract
To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of irinotecan and raltitrexed given as sequential short infusions every 3 weeks, 33 patients with pretreated gastrointestinal adenocarcinoma (31 colorectal, 2 oesophagogastric) entered this open label dose-escalation study. For the first five dose levels patients received irinotecan 175–350 mg m–2followed by raltitrexed 2.6 mg m–2. Level VI was irinotecan 350 mg m–2plus raltitrexed 3.0 mg m–2, level VII was irinotecan 400 mg m–2plus raltitrexed 2.6 mg m–2; 261 courses were administered. Only one patient at dose levels I–V experienced DLT. At level VI, 5/12 patients experienced DLT: one had grade 3 diarrhoea and lethargy, one had grade 4 diarrhoea and one had lethargy alone. Two others had lethargy caused by disease progression. There was no first-cycle neutropenia. At level VII, 3/6 patients experienced dose-limiting lethargy, one also had grade 3 diarrhoea. Dose intensity fell from over 90% for both drugs at level VI to 83% for irinotecan and 66% for raltitrexed at level VII. Lethargy was therefore the DLT, and level VII the MTD. Pharmacokinetic data showed no measurable drug interaction; 6/30 patients (20%) had objective responses. This combination is active with manageable toxicity. Recommended doses for further evaluation are irinotecan 350 mg m–2and raltitrexed 3.0 mg m–2. © 2000 Cancer Research Campaig
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 11/12/2019